Trial
NCT04373044
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI)
Condition
Symptomatic COVID-19 Infection Laboratory-Confirmed
Intervention
Baricitinib
Why stopped
The study was terminated after the release of results of ACTT-2 (NCT04401579).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-26